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Abstract
Aims The aim of this study was to evaluate the risk factors of
lymph nodes metastases (LNM) in patients with papillary
thyroid cancer (PTC) and coexisting Hashimoto’s thyroiditis
(HT).
Patients and methods This was a retrospective cohort study of
patients with PTC and HT who had undergone total thyroid-
ectomy (TT) with central neck dissection (CND) over an 11-
year period (between 2002 and 2012). Pathological reports of
all eligible patients were reviewed. Multivariable analysis was
performed to identify risk factors of LNM.
Results During the study period, PTC was diagnosed in 130
patients with HT who had undergone TT with CND (F/M
ratio=110:20; median age, 52.4±12.7 years). Multifocal le-
sions were observed in 28 (21.5 %) patients. LNM were
identified in 25 of 28 (89.3 %) patients with multifocal PTC
and HT versus 69 of 102 (67.5 %) patients with a solitary
focus of PTC and HT (p=0.023). In multivariable analysis,
multifocal disease was identified as an independent risk factor
for LNM (odds ratio, 3.99; 95 % confidence interval, 1.12 to
14.15; p=0.033).
Conclusions Multifocal PTC in patients with HT is associated
with an increased risk of LNM. Nevertheless, the clinical
importance of this finding needs to be validated in well-
designed prospective studies.
Keywords Hashimoto’s thyroiditis . Multifocal papillary
thyroid cancer . Benign thyroid disease
Introduction
Papillary thyroid cancer (PTC) is among the most common
forms of thyroid carcinomas, and its incidence has been rap-
idly increasing over the last years, coexisting with autoim-
mune Hashimoto’s thyroiditis-type thyroid diseases.
Numerous data from the literature on the subject and multi-
center meta-analyses demonstrate that PTC coexists almost
three times more often with Hashimoto’s thyroiditis, and its
concomitant occurrence reported in various publications
ranges between 0.5 and 58 %. There are no unambiguous
premises for stating whether an autoimmune disease predis-
poses to cancer development or else whether, in the course of
cell transformation in the carcinogenesis process, there occurs
a change in the autoimmune response that favors the devel-
opment of such a disease. It is muchmore common in younger
women with small primary foci or with multifocal disease and
a statistically better prognosis as compared to the remaining
patients [1–9].
Although the pathogenesis still remains highly controver-
sial, the immune background of the disease, which involves
activation of T-helper and T-cytotoxic lymphocytes and over-
production of specific antibodies (anti-TPO; anti-TG) favors
papillary cell damage, leading in consequence to hypothyroid-
ism. The relation between Hashimoto’s thyroiditis and papil-
lary thyroid carcinoma, described for the first time by Daley in
1955, still continues to be a subject of discussion and attempts
at explaining the phenomenon [10, 11].
On the one hand, it is suggested that under specific condi-
tions, development of Hashimoto’s disease is a response to
cancer cells appearing within the thyroid gland, while on the
other, data are reported in support of a thesis that the observed
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morphological lesions in the thyroid result from immune
disturbances leading to imbalance between natural death of a
cell in keeping with the mechanism of apoptosis and uncon-
trolled proliferation of the cell [12, 13].
The objective of the report that is based on material col-
lected at the department is to present the occurrence of lymph
node metastases to the central compartment of the neck that
coexist with the multifocal form of papillary thyroid cancer
concomitant with Hashimoto’s thyroiditis. In the opinion of
the authors, an early detection of such lesions, selection of an
appropriate strategy of surgical management performed in
selected referral centers, targeted adjuvant therapy, and treat-
ment monitoring at the same time meeting the safety require-
ment of protecting the laryngeal nerves and preventing hypo-
parathyroidism may play a significant role in improving late
therapeutic results [14].
Materials and methods
Between January 2002 and December 2012, of 9,145 patients
treated surgically in a single referral university center due to
various thyroid diseases, a subgroup of 548 patients diagnosed
with Hashimoto’s thyroiditis and coexistent papillary thyroid
cancer was selected. The mean age of the patients was 52.4±
12.7 years and the female to male ratio was 464:84, respec-
tively. Table 1 presents the demographic data of the study
group. The analyzed group of patients with Hashimoto’s
thyroiditis included all individuals meeting the following
criteria: (1) high anti-thyroid peroxidase antibodies titers
(anti-TPO), (2) lesions visualized by ultrasonography show-
ing a hypoechoic or hyperechoic nodular pattern at least 5 mm
in diameter, identification of a perinodular hypoechogenic or
hyperechogenic halo and presence of an anechoic lesion with
a reinforced posterior wall, (3) histology: presence of a diffuse
lymphocytic infiltrate in the thyroid parenchyma and stroma
with reaction foci and lymphatic follicles, presence of small
follicles with a decreased colloid volume, foci of fibrosis and
oxyphilic cytoplasm-containing cells. A repeated analysis of
FNA results based on the 2009 Bethesda classification
showed the descriptions of findings to most commonly in-
clude lesions that would be presently classified as belonging
to grades III and IV.
The exclusion criteria included patients positive for
thyroid-stimulating hormone receptor antibodies (TRAb),
Graves’ disease in medical history, and absence of clinical,
ultrasound, and morphological signs of Hashimoto’s
thyroiditis.
In the non-HT group, indications for surgical treatment
included suspicious lesions detected by fine needle aspiration
biopsy (FNAB; Bethesda grades III and IV: III—atypia of
undetermined significance or follicular lesion of undeter-
mined significance; IV—follicular neoplasm or suspicious
for follicular neoplasm (Hurthle cell)), signs of compression
of the trachea and surrounding tissues, multinodular toxic
goiter, and Graves’ disease [15–17].
In keeping with the surgical management tactics adopted
by the center represented by the authors, the scope of the
primary operations performed in the presented group of pa-
tients with nodular variant of Hashimoto’s thyroiditis included
total thyroidectomy combined with resection of the lymphatic
system situated in the central compartment of the neck in 93%
of the patients; in the remaining individuals, subtotal bilateral
lobectomies were performed. Final histology confirming a
neoplastic pattern was an indication for total resection of
residual thyroid tissue [18, 19].
All the procedures were performed by an experienced team
of surgeons. In all the total thyroidectomy cases, the operation
included extracapsular bilateral lobectomy combined with
resection of the Delphic pretracheal and paratracheal lymph
nodes (according to the American Thyroid Association clas-
sification) [20, 21].
In the majority of the patients with positive preoper-
ative FNA biopsy results indicative of papillary thyroid
cancer, identification of laryngeal nerves was achieved
by intraoperative nerve monitoring: NEUROSIGN 100
System (Inomed, Emmendingen, Germany), which was
used between the years 2004 and 2008, or NIM-
Response 3.0 System (Medtronic Xomed, Jacksonville,
FL), which was used between the years 2009 and 2012.
In each instance, attempts were made to identify the
four parathyroids and leave them in situ, exercising
caution while dissecting the thyroid. In each case of
parathyroid resection or doubts as to the appropriate
parathyroids vasculature, the gland was reimplanted to
the sternocleidomastoid muscle on the side of the orig-
inal parathyroid location. The assessment of cancer
stage was based on the seventh edition of the TNM
classification of 2010. The histology results based on
Table 1 Clinical and pathological factors characteristics of 9,145 pa-
tients undergoing surgery in the years 2002–2012
HT
(n=548)
Non-HT
(n=8,597)
P
Age, mean ± SD (years) 52.4±12.7 53.3±15.2 0.739
Sex ratio (M/F), no. 84 : 464 812 : 7785 0.484
Preoperative thyroid volume
(by ultrasound), mean ±
SD (ml)
22.1±18.2 96.2±40.4 <0.001
Anti-TPO (IU/ml) 428.6±627.8 12.3±7.8 <0.001
Preoperative diagnosis of
benign thyroid disease, no. (%)
501 (91.4) 8,279 (96.3) <0.001
Positive FNAB for PTC, no. (%) 47 (8.6) 318 (3.7) <0.001
HT Hashimoto thyroiditis, FNAB fine needle aspiration biopsy, PTC
papillary thyroid cancer
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the repeated analysis of histological records stored in
the Institutional Register of Thyroid Surgery were clas-
sified based on the above-presented assumptions.
Examinations performed in all the patients qualified for
surgical treatment included thyroid ultrasonography and de-
terminations of fT4, fT3, thyroid-stimulating hormone (TSH),
and anti-TPO and anti-TG antibodies. In all the patients pre-
senting with clinical and biochemical signs of hypothyreosis,
levothyroxine substitution was initiated preoperatively. In the
analyzed group, the mean follow-up was 5.1±2.4 years. In
each instance, in the first postoperative day, indirect laryngos-
copy was performed and calcium levels were determined;
hypocalcemia was diagnosed at total calcium levels below
2.0 mmol/l.
In all the patients after thyroid parenchyma resection and
following establishing the diagnosis of differentiated thyroid
cancer, a uniform therapeutic management strategy was
adopted based on supplementation therapy with radioiodine
in case of tumors with the diameter of >10mm, administration
of levothyroxine (at a dose providing a suppression level for
TSH values 0.1–0.3 mU/L in the low-risk group and below
0.1 mU/L in the high-risk group), strict periodic determina-
tions of TSH, TG, and anti-TG levels. The above management
protocol is based on the recommendations of the Polish Group
of Endocrine Tumors of 2010 [22].
In the statistical analysis, the comparison of variables with
normal distribution was based on the Student’s t test, while the
remaining variables were analyzed employing the χ2 test. In
the analyzed group, the “exposure” to the presented factors
was determined based on the odds ratio. The multivariate
analysis of lymph node metastases risk factors in case of
coexisting HT-PTC was based on gender, age, smoking, cen-
tral neck dissection, tumor size, multifocal disease, extension
through the thyroid capsule, positive lymph nodes, and RAI
treatment. Variables achieving statistical significance at
the p≤0.10 level in the univariable analysis were in-
cluded in the multivariable analysis. A backward vari-
able selection procedure with the cut-off at P<0.050
was used to identify independent predictors of central
lymph nodes involvement in HT.
All the data were collected prospectively and stored in a
computer-based institutional register of thyroid surgery and
analyzed retrospectively by a statistician. The statistical anal-
yses were performed with Statistica 10 forWindows (StatSoft,
Krakow, Poland).
Results
The analyzed group of 548 patients with Hashimoto’s thy-
roiditis included 130 (23.5 %) cases of papillary thyroid
carcinoma (HT-PTC) as compared to 643 (7.5 %) cancer
patients in the group of 8,597 patients (non-HT-PTC) without
diagnosed autoimmune disease. The values were statistically
significant (p<0.001). In the two analyzed groups, the ratio of
males to females was different (HT-PTC group=1:6; non-HT-
PTC group=1:10 The mean age and number of the surgical
patients in the two analyzed groups were similar, showing the
following respective values: (HT-PT group, 52.4±12.7 versus
non-HT-PTC group, 53.3±15.2) and (<45 years: HT-PTC
group: 52=40.0 % versus non-HT-PTC group: 278=43.2 %;
≥45 years: HT-PTC group: 78=60.0 % versus non-HT-PTC
group: 365=56.8 %).
The size of goiter in the two analyzed groups assessed
based on preoperative ultrasound volume measurements was
markedly different (HT-PTC group=22.1±18.2; non-HT-PTC
group=96.2±40.4). The difference was statistically signifi-
cant (p<0.001). Also, the difference in preoperative anti-
TPO titers was statistically significant (p<0.001) (HT-PTC
group=428.6±627.8; non-HT-PTC group=12.3±7.8).
Preoperatively, a positive result of fine needle aspiration bi-
opsy (Bethesda grades Vand VI) was noted in 47 (36.2 %) of
130 patients with HT-PTC. In the remaining cases, in the
biopsy smears (FNAB—Bethesda grades III and IV), oxy-
philic cells predominated along with lymphocytes and mac-
rophages (Table 1).
According to the American Joint Committee on Cancer/
Union Internationale Contre le Cancer, stage pT1a papillary
thyroid cancer was diagnosed in 80 (61.7 %) patients with
Hashimoto’s thyroiditis and was predominant as com-
pared to the remaining analyzed group (pT1a: HT-PTC group:
80=14.6 % versus non-HT-PTC group: 365=2.24 %;
p<0.001).
Multifocal cancer was noted in 28 (pTm=21.5 %; respec-
tively: pT1m=25 (19.2 %); pT2m=1 (0.8 %); pT3m=2
(1.5 %)) patients with Hashimoto’s thyroiditis (HT-PTC
group: 28=5.1 % versus non-HT-PTC group: 121=1.4 %).
The multifocal form was defined as the presence of two or
more neoplastic foci in one or both thyroid lobes. The diam-
eter of the largest single neoplastic focus in the two analyzed
groups was similar (HT-PT group: 8.7±5.9 versus non-HT-
PTC group: 9.4±6.9); nevertheless, in a considerable number
of patients (pT1m: HT-PTC: 28=21.5 %), the lesions were
10–12 and 2–3 mm in size, respectively, and were located
bilaterally. The size of primary focus: tumor size (millimeters)
<10 mm=80 patients; ≥10 mm=50; with infiltration of the
thyroid capsule in 16 patients (in the group of patients with
tumors >20mm). Thyroid capsule infiltration predominated in
unifocal forms. In multifocal tumors, the lesions usually
involved both thyroid lobes and were situated in the
central part of the gland or in the vicinity of the inferior
poles, surrounded by lymphocyte infiltrations and the
remaining thyroid tissue. Such a location of lesions in a
great measure reflects our knowledge on the lymphatic
outflow routes from the thyroid to the central lymph
nodes, at the same time explaining the number of the
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involved central compartment cervical lymph nodes in
the presently analyzed material.
A statistically significant difference was seen in lymph
node metastases to the central compartment of the neck (com-
partment VI). LNM were identified in 25 of 28 (89.3 %)
patients with multifocal PTC and HT versus 69 of 102
(67.5 %) patients with a solitary focus in the HT-PTC group
(p=0.023). In patients with HT, preparations originating from
the compartment VI demonstrated respectively a higher num-
ber of resected and a higher number of metastatically involved
lymph nodes as compared to the remaining group of non-HT
patients (HT-PTC group: 13.8±3.7 versus non-HT-PTC
group: 6.5±2.7 and HT-PTC group 6.4±2.7 versus non-HT-
PTC group: 2.1±1.0) (Fig. 1; Table 2).
In the multivariable analysis, multifocal disease was iden-
tified as an independent risk factor for LNM (odds ratio, 3.99;
95 % confidence interval, 1.12 to 14.15; p=0.033) (Table 3).
No significant differences were observed between the HT-
PTC patients versus non-HT-PTC patients (Table 4) with
respect to the prevalence of complications following
thyroidectomy.
Discussion
More than 100 years after Hashimoto’s thyroiditis was first
described, its etiology still remains not fully understood. Until
early 50s of the last century, HTwas a rarely described disease
entity. The discovery and description of an unambiguous
relationship between HT and papillary thyroid cancer by
Dailey et al. in 1955 made numerous authors search for the
causes of the phenomenon [23].
At present, according to numerous meta-analyses and data
from the literature on the subject [1, 9, 24], papillary thyroid
cancer coexists with Hashimoto’s thyroiditis approximately
three times more often and the percentage of PTC in various
reports is within a considerably sharp range of 0.5 % to above
58 %, with a peak at 76 % in a selected group of patients from
Japanese and American populations (white American wom-
en). A visible increase in the incidence of the two diseases
coexisting has been also observed within the past 20 years.
This situation is undoubtedly affected by an increase in the
incidence of autoimmune thyroid diseases, improvement of
ultrasound techniques, higher availability of biopsy, or higher
awareness of patients [1, 9, 13, 24–26].
Similarly as in the above quoted literature, in the presently
analyzed material, in 23.5 % of the patients, papillary thyroid
cancer coexisted with Hashimoto’s thyroiditis-type lesions. A
threefold increase of the incidence of papillary thyroid cancer
with the background of chronic autoimmune thyroiditis as
compared to all patients with this cancer unambiguously
points to an autoimmune background of the disease (HT-
PTC: 130=23.5 % versus non-HT-PTC: 643=7.5 %).
The results presented in earlier and contemporary reports
suggest that HT-PTC is significantly more frequently seen in
Fig. 1 Specimen of en-block resected thyroid gland with level VI lymph
nodes
Table 2 Final histopathology in 773 patients with PTC involved in this
study in relation to the Hashimoto thyroiditis
PTC with
HT (n=130)
PTC in non-
HT (n=643)
P
Sex ratio (M/F) 20:110 69:574 0.129
Age at diagnosis (years)
<45 52 (40.0) 278 (43.2) 0.496
≥45 78 (60.0) 365 (56.8) 0.496
pT1a 80 (61.5) 391 (61.7) 0.569
pT1b 22 (14.6) 57 (8.9) 0.006
pT2 12 (9.2) 78 (12.1) 0.295
pT3 16 (12.6) 108 (16.9) 0.168
Multifocal lesions 28 (21.5) 121 (18.8) 0.469
pN1a 94 (72.3) 221 (34.9) <0.001
pT1aN1a 47 (36.1) 37 (5.8) <0.001
pT1bN1a 18 (13.8) 51 (7.9) 0.031
pT2N1a 2 (1.5) 15 (2.3) 0.573
pT3N1a 11 (8.5) 87 (13.7) 0.094
Multifocal lesions and N1a 25 (19.2) 51 (7.9) <0.001
Diameter of the largest foci in
mm, mean ± SD
8.7±5.9 9.4±6.9 0.437
Number of removed lymph nodes
within level VI, mean ± SD
13.8±3.7 6.5±2.7 <0.001
Number of macrometastatic
lymph nodes, mean ± SD
6.4±2.7 2.1±1.0 <0.001
PTC was diagnosed in 130/548 (23.5 %) HT patients versus 643/8,597
(7.5 %) non-HT patients (p<0.001)
HTHashimoto thyroiditis, PTC papillary thyroid cancer
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the population of females in a lower age range, presenting
with small lesions not exceeding 10 mm, multifocal disease,
but also with statistically better prognoses as compared to the
remaining group of patients. In the present study, women
prevailed in both groups (p<0.001), being aged slightly over
45 years, and the autoimmune background coexisted with
multifocal form of papillary thyroid cancer with small primary
foci (pT1a) [27–33].
To date, there has not been formulated a definite and
unambiguous position on predisposition to development or
inhibition of neoplastic process in patients with Hashimoto’s
thyroiditis. Numerous publications on the subject only report
final conclusions based on population studies [31, 32].
The presence of an autoimmune disease facilitates devel-
opment of neoplastic lesions, but it is not entirely clear wheth-
er the disease per se predisposes to cancer development or
whether it may provide a protective barrier against its spread
as lymph node metastases or local recurrent disease [33].
At present, an important role in the pathogenesis of thyroid
autoimmune diseases is played: FasL molecule and Fas recep-
tor, inhibitor molecule like Bcl-2 protein, and the most com-
mon mutations in thyroid cancer include RET/PTC rearrange-
ment, BRAF mutation, RAS mutation, or finally rearrange-
ments leading to formation of PAX8-PPARg fusion oncogene.
At present, the best known mutation form in papillary thyroid
cancer is RET/PTC1 and RET/PTC3 sequence, also encoun-
tered in Hashimoto’s thyroiditis. Shel et al. detected RET/
PTC1 mutation in as many as 95 % investigated patients,
although they presented without clinical manifestation of le-
sions involving thyroid parenchyma. In view of the possible
analysis of the BRAF gene originating from biopsy material
(FNAB), reports have been published on employing the test to
define high-risk groups.
We do not know which of the above-presented factors
could have affected the number of metastases and the number
of diagnosed cases of papillary thyroid cancer in the present
material; nevertheless, we have noted both a high percentage
(130=23.5 %) of papillary thyroid cancers (HT-PTC) as com-
pared to (643=7.5 %) cancer patients in the non-HT-PTC
individuals without the autoimmune disease and a statistically
significant difference with respect to lymph node metastases
to the central compartment of the neck (LNM: HT-PTC group:
94 of 130 (72.3 %) versus non-HT-PTC group: 164 of 643
(25.5 %)) [34–45].
Thus, molecular studies may become an important element
of cytological diagnostic management, by the same token
decreasing the number of dubious diagnoses. The consider-
able differences in biopsy results (0.4 %—Matesa et al. to
92 %—Singh et al.) may be a consequence of differences in
defining lesions that require thyroid cytological diagnostic
management in patients with Hashimoto’s thyroiditis [1, 46].
In the present material, the diagnosis of papillary thyroid
cancer was confirmed in biopsy material only in 47 of 548
(8.04 %) HT patients. Although the number is very low, it is
also confirmed in the literature on the subject. In all the
remaining cases of limited nodular lesions situated in the
thyroid parenchyma, specificity and sensitivity of the test
was high, above 90 %. It is difficult to unequivocally state
whether this occurs due to lymphocytic infiltrations,
Table 3 Univariable analysis of factor associated with lymph node
metastases in 130 patients with PTC and HT involved in this study
No. of patients Lymph nodes metastases (n=94)
Odds ratio (95 % CI) P
Sex
M 20 0.10 (0.037–0.31) <0.001
F 110 1.00
Age (years)
<45 52 0.29 (0.14–0.66) 0.003
≥45 78 1.00
Smoker
Yes 53 0.37 (0.16–0.81) 0.482
No 74 1.00
Tumor size (mm)
<10mm 80 3.02 (1.45–6.25) 0.003
≥10mm 50 1.00
Multifocal disease
Yes 28 3.99 (1.12–14.15) 0.033
No 102 1.00
Extension through thyroid capsule
Yes 16 0.44 (0.15–1.28) 0.133
No 114 1.00
Table 4 Complications after thyroidectomy in 773 patients with PTC
involved in this study in relation to the Hashimoto thyroiditis
PTC in HT
(n=130)
PTC in Non-
HT (n=643)
P
Parathyroid found in
pathological report, no. (%)
16 (12.3) 52 (8.2) 0.121
Hypoparathyroidism, no. (%)
Total 48 (36.9) 216 (34.1) 0.465
Transient 45 (34.6) 203 (32.0) 0.498
Permanent 3 (2.3) 13 (2.0) 0.835
Unilateral RLN injury, no. (%)a
Total 13 (5.0) 58 (4.5) 0.731
Transient 9 (3.5) 43 (3.3) 0.923
Permanent 4 (1.5) 15 (1.2) 0.619
HT Hashimoto thyroiditis, PTC papillary thyroid cancer, RLN recurrent
laryngeal nerve
a RLN injury was calculated for nerves at risk and not for patients (there
were 260 nerves at risk in PTC with HT group and 1,286 nerves at risk in
PTC non-HT group)
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displacement of papillary cells by lymphocytes, or formation
of reaction centers surrounding the primary focus. As it has
been mentioned above, to date we do not know whether the
presence of the afore-mentioned infiltrations is a factor that
predisposes to tumor development or a reaction of the body to
neoplastic disease. Diagnostic problems in evaluation of
FNAB results continue to be stressed, both with respect to
false-negative results and to overinterpretation of microscopic
images with false-positive results [47–49].
A significant element in clinical assessment of papillary
thyroid cancer is the size of a primary focus. As it has been
mentioned, papillary thyroid cancer is generally characterized
by a favorable prognosis. This is particularly true of patients
with well-differentiated pT1a stage cancers, which do not
exceed 10 mm in diameter. It should be noted, however, that
even these forms show a fairly high capability to form meta-
static foci. In the analyzed material, lymph node metastases to
the central compartment of the neck were significantly more
numerous in patients with cancer and Hashimoto’s thyroiditis.
Ultrasonographic findings predominantly showed non-
specific enlargement of cervical lymph nodes of the central
compartment. The size of the primary focus in the majority of
cases (80=61.7 %) did not exceed 10 mm (mean 8.7±
5.9 mm), and although the mean value was higher than the
size reported by other authors, nevertheless, it provided a basis
for diagnosing microcarcinomas [50, 51].
The multifocal form of papillary thyroid carcinoma in
patients with Hashimoto’s disease was diagnosed in 28
(5.1 %) patients; in this group, 25 (89.3 %) metastases to the
central compartment were observed. Thus, in light of data
from the literature, one may assume that the size of the
primary focus does not determine the presence or absence of
lymph node metastases and coexistence of an autoimmune
disease and papillary thyroid cancer does not significantly
affect the number of foci but often coexists with their smaller
size. Thus, Hashimoto’s thyroiditis may play a protective role,
triggering improvement of therapeutic results and, by the
same token, also improving the prognosis. Such data have
been extensively reflected in the literature on the subject [33,
52–56].
Based on their observations of the two groups of patients,
the present authors have concluded that coexistence of
Hashimoto’s thyroiditis and papillary thyroid cancer is a more
common phenomenon and affects almost one fourth of all
patients. In the meta-analysis published in 2013, such a diag-
nosis accounts for only 1.2 % of biopsy diagnoses as com-
pared to 27.6 % of ultimate results of histology following
thyroidectomies. In turn, Shih et al. analyzed 474 surgical
patients with coexistingHTand found papillary thyroid cancer
in final histology in as many as 53 %, while “only” 28.05 %
tumors were found in preoperative FNAB [57]. Thus, the
remaining group consisted of patients without clinical and
cytological features of neoplastic disease. Similar
observations were made by Chinese authors—Lun et al. [33]
emphasized differences in incidence of papillary cancer in
patients with coexisting Hashimoto’s thyroiditis as compared
to patients with preoperative diagnosis of nodular goiter (18.8
versus 7.2 %). The said authors also suggested that indepen-
dent factors of cancer development included elevated serum
TG antibody and TSH titers in patients with autoimmune
thyroid disease [33].
And thus, may we passively observe patients with
coexisting nodular lesions and Hashimoto’s thyroiditis? The
question continues to be highly controversial [33, 49, 57].
Numerous authors are still inclined to employ markedly
more conservative treatment of Hashimoto’s thyroiditis in
keeping with the assumptions presented by Thomas et al. in
1981 in the Annals of Surgery that patients referred for surgical
treatment of HT should meet the following criteria: the pres-
ence of a dominant mass with incomplete regression on sup-
pressive therapy; progression of thyromegaly despite suppres-
sive therapy; history or physical findings suggesting malig-
nancy, e.g., irradiation, multiple endocrine adenomatosis syn-
drome, nerve paralysis, pain, tracheal compression, stipple
calcification, and cervical lymph node enlargement; and the
last: positive findings in FNAB. Such a position supports the
view shared by some authors that treatment of Hashimoto’s
thyroiditis is associated with a statistically higher probability
of postoperative complications manifested as hypocalcemia
and laryngeal nerves palsy [58, 59].
The above-presented various therapeutic strategies
employed in patients with Hashimoto’s thyroiditis have led
the present authors to presenting their own opinion. It is our
belief that in view of the relatively high percentage of PTC in
HT, the proposed strategy of surgical HT treatment should be
total thyroidectomy. Prophylactic lymphadenectomy of com-
partment VI cervical lymph nodes remains to be considered,
as it allows for a correct determination of the stage of a
possible neoplastic disease and indications for further adju-
vant therapy. Increasingly more often reports are published
stating that primary total thyroidectomy not only allows for
treating a disease already diagnosed based on the FNAB result
but also contributes to decreasing the incidence of
reoperations due to postoperative diagnosis of thyroid cancer.
Analyzing the above-presented assumptions for treatment of
Hashimoto’s thyroiditis with coexisting nodular lesions, we
have to strongly emphasize that total thyroidectomy with
resection of central compartment lymph nodes may be asso-
ciated with damage to the recurrent laryngeal nerves and an
inadvertent resection of inferior parathyroid glands.
Nevertheless, we believe that the incidence of such complica-
tions in referral centers is low and comparable to operations
performed due to indications other than autoimmune disease.
In our material, we have not observed significant differences
in the incidence of complications in patients with diagnosed
papillary cancer with coexisting Hashimoto’s thyroiditis as
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compared to the remaining group [14, 18]. This point, ex-
tremely important in the context of the proposed radical pro-
cedures, is fully justified with respect to the presented in our
material low diagnostic value of preoperative FNAB in nod-
ular lesions and a simultaneous increase in incidence rates of
cancer concomitant with Hashimoto’s thyroiditis in histology
materials (the presence of PTC inHT being threefold higher as
compared to the non-HT-PTC group).
It should be, however, stressed that the above assumptions
are valid for referral centers, to which patients with HTshould
be sent. We believe that dissemination of this “radical thyroid
surgery” strategy to low-volume thyroid surgery units should
be preceded by extensive and well-designed training pro-
grams, followed by strict quality control assurance being
now possible in some countries [18].
And thus, in our opinion, radical surgical treatment of
patients with Hashimoto’s thyroiditis is an important prognos-
tic factor in the strategy of therapeutic management that
allows—in cases of diagnosing thyroid cancer—for initiating
effective radioiodine adjuvant therapy, decreases the risk of
local and regional recurrent disease, and facilitates postoper-
ative patient monitoring through increasing sensitivity of
postoperative TG determinations. In our view, the
abovementioned considerations provide a good basis for tak-
ing into account radical surgical treatment based on the “cost–
benefit” principles in cases with nodular lesions being present
in an immunologically altered thyroid gland [14, 18, 19].
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